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Editorial
The medicinal chemistry field is in a period 
of crisis, mirrored in the low number of new 
drug approvals, especially considering the paral-
lel increasing levels of investments in research. 
This happens when, at the same time, combina-
torial chemistry and high-throughput screening 
increased the number of tested substances and 
the redutionistic approach (the magic bullet 
against a target assayed in in vitro test systems) 
was followed for the development of new drugs, 
in order to reduce promiscuity (off-target inter-
actions), which was linked to the appearance of 
side effects [1]. 
However, this approach proved to be only 
partially successful, since, for first-in-class 
molecules approved by the US FDA between 
1999 and 2008, a period of time in which the 
target-directed strategy was the main approach 
for new pharmacologically active compounds, 
37% resulted from projects that used phenotypic 
screening and only 23% from target screening. 
This statistic is all the more startling consider-
ing the wider popularity of target screening with 
respect to phenotype [2]. At the same time, it 
is becoming clear that many drugs may derive 
their therapeutic action (and/or their off-target 
activities) from the interactions with multiple 
proteins; for noncancerous diseases, the average 
number of interaction partners for protein tar-
gets of marketed drugs is 4.24, and for cancer 
targets it is 7.82 [3]. Thus, it looks that many 
clinically useful drugs are multitarget agents. 
In fact, except for diseases caused by mutation 
or elimination of specific genes, many others for 
example, cancer, metabolic disorders and CNS 
diseases, are multifactorial; it is becoming clear 
that disease states are resistant to perturbations 
and maintain their state through mechanisms 
such as back-up circuits and fail-safe mecha-
nisms. Moreover, cancer and infectious diseases 
are characterized by the appearance of resistance, 
owing to the selection of one or more mutations 
in encoded target proteins [4–6]. These findings 
give the rationale for the use of drugs able to 
target multiple, unrelated proteins. Accord-
ingly, drug associations gained popularity as 
therapeutic, multitarget agents [7]. 
Medicinal chemistry research addressed this 
point by the design of multitarget agents. The 
procedure of the discovery of these agents was 
based on in vivo assays or the design of assembled 
pharmacophores of the target ligands under con-
sideration, with or without the aid of computa-
tional techniques. These procedures were dem-
onstrated to be successful in some disease areas; 
some of the compounds thus obtained entered 
clinical trials (e.g., drugs used to treat psychiatric 
disorders), but few compounds became clinically 
available [7]. Perhaps the most successful exam-
ple of recently discovered multi-target drugs is 
kinase inhibitors as anti-angiogenesis anticancer 
agents. Achieving a durable and efficient anti-
angiogenic response requires approaches to 
simultaneously or sequentially target multiple 
aspects of the tumor microenvironment [8]. In 
this case, it is relatively easy to obtain a drug-like 
inhibitor, since kinases (more than 500) share a 
very similar binding site for ATP, which becomes 
the binding site of the inhibitors; the problem 
in this case is to obtain selectively nonselective 
compounds using the subtle differences in the 
binding sites.
The development of sunitinib, one of the first 
multikinase inhibitors approved (2006), started 
as a selective VEGFR2 inhibitor drug, but dur-
ing the project evolution, the target was broad-
ened since it was hypothesized that simultaneous 
inhibition of multiple RTK, critical to regulation 
of both tumor proliferation and angiogenesis, 
would cooperate to produce anti-tumor efficacy. 
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The product was optimized through action on 
VEGFR and PDGFR kinases [9], but after it was 
shown that its selectivity depends on the num-
ber of kinases tested, a characteristic shared by 
almost all known designed (multi)kinase inhibi-
tors. When tested on all kinases available (more 
than 400, KINOMEscan® platform), sunitinib 
showed a score S of 0.569 at 3 µM concentration 
and of 0.183 at 100 nM (S: ratio between the 
number of kinases found to bind to the drug 
with K
d
 less than 3 µM or K
d
 less than 100 nM, 
and the total number of kinases tested); thus, 
a great number of kinases are inhibited by this 
drug [10], and the compound appears to actually 
be a nonselective multitarget compound. This 
compound demonstrated that it was able to make 
some tumors more aggressive in animal models 
[11,12]; this is probably due to the drug-induced 
hypoxia that activates the Akt/b-catenin path-
way which, in turn, stimulates the growth of spe-
cific, more aggressive, cancer cells populations. A 
solution that has been hypothesized to overcome 
this problem is represented by the combination 
(coadministration) of anti-angiogenic inhibi-
tors with drugs able to block the cancer cell 
response to hypoxia or with compounds able to 
block Akt/b-catenin pathway [13]. Thus, only a 
full understanding of the networks present in a 
cancer cell can aid in the selection of the appro-
priate targets to fight this, and other, complex, 
multifactorial diseases. Another study suggested 
that the off-target effects of the RTK inhibitor 
could be responsible for the disruption of the 
homeostatic barrier function of the host vascula-
ture, with the consequent metastasis promotion 
observed [14].
Drug design using modern procedures, such 
as the fragment-based approach, do not guaran-
tee that off-target activities are absent: sorafenib, 
a multikinase inhibitor discovered following this 
strategy [15], was recently shown to be a nano-
molar antagonist of the 5-HT receptors [16]. This 
issue probably will be successfully reduced in the 
future by means of in silico procedures, since 
computational chemistry is developing strategies 
to predict the promiscuous binding propensities 
of drug molecules [16]. 
Thus, the available technologies are able to 
allow the design of clinically useful multi target 
agents [7,17], but these procedures have to be inte-
grated with phenotype screening [18] and a proper 
selection of targets relevant for a given pathol-
ogy. Problems linked on relying only on in vitro 
assays have been considered in the development 
of multikinase inhibitors: translating the isolated 
enzyme inhibition to efficacy against the native 
kinase needs cell-based assays in order to take 
into account intracellular ATP concentrations, 
membrane permeability, presence of phosphatase 
enzymes and the relative concentrations of the 
kinase targets and their substrates [10].
While there is a research of modern pheno-
typic assays [18], network pharmacology deals 
with the second problem, namely the proper 
selection of the targets. Cellular activity and 
response following the interaction of molecules 
with biological targets comprises interaction 
with multiple components (networks: protein–
protein interactions, protein–DNA interactions, 
epigenetic changes, together with changes in 
metabolic and functional pathways); these 
interactions are networked at the organ and 
subsequently at the organism level. Network 
pharmacology targets the myriad of interaction 
networks between molecules into cells, instead 
of targeting a single protein; systems biology, 
in turn, studies how the sum of all interac-
tions between the molecules in a cell creates a 
greater whole [19]. This field has already revealed 
a number of promising examples of rational 
and network-based drug-target predictions, 
successfully tested also in vivo [7,19]. 
At least two companies are grounded on 
network pharmacology to find out new drugs. 
E-therapeutics, with its proprietary network 
pharmacology platform, is able to analyze net-
work of proteins associated with a particular 
disease; in this way, it is possible to identify 
a disease signature, proteins in the network 
at which intervention would have maximum 
impact. The scientists mapped out 103 pro-
tein networks that help cancer cells to evade 
“Medicinal chemistry research addressed this 
point by the design of multitarget agents. The 
procedure of the discovery of these agents was 
based on in vivo assays or the design of 
assembled pharmacophores of the target 
ligands under consideration, with or without the 
aid of computational techniques.”
“This issue probably will be successfully reduced 
in the future by means of in silico procedures, 
since computational chemistry is developing 
strategies to predict the promiscuous binding 
propensities of drug molecules.”
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apoptosis, then selected a drug, previously 
known as safe but ineffective in Phase III stud-
ies, dexanabinol, able to modulate the network 
(a sort of drug rescue, in which promising 
compounds that have been developed for one 
indication but have failed to reach the clinic 
are redirected toward another indication). The 
product showed to be active on cancer cell 
lines and it is now in Phase I clinical studies 
for the treatment of glioma. Another company, 
Pharnext, is studying in Phase II PXT3003, a 
combination of the GABA agonist, baclofen, 
opioid receptor antagonist, naltrexone and sor-
bitol, as a therapeutic treatment for neuropathic 
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Charcot–Marie–Tooth disease [20]. If clinically 
successful, network pharmacology surely will 
heavily modify the drug-discovery process.
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